All In Capital leads pre-seed round in healthcare infrastructure startup Tross
3 min read
- By | August 20, 2026
Tross secured an undisclosed sum in a pre‑seed round led by All in Capital, with DeVC also taking part. The healthcare‑focused startup plans to allocate the capital to enhance its product, grow its engineering staff, increase EHR and payer connections, and broaden its footprint across the US health sector.
Key Takeaways
- Healthcare infrastructure startup Tross raised an undisclosed pre-seed round led by All In Capital, with DeVC also participating.
- Founders Padam Kataria and Meet Shah (formerly operating as Ayden) aim to build a tech layer connecting AI firms with hospital, payer and provider systems.
- Funds will enhance the product, grow engineering staff and increase EHR and payer connections.
- The company targets interoperability challenges that scatter critical healthcare data across disparate systems.
Founders Padam Kataria and Meet Shah launched Tross to create a tech layer that lets AI firms link with the intricate systems employed by hospitals, physicians, insurers, and other health‑care entities. The company formerly operated under the name Ayden.
While it might appear to be a back‑end technical issue, it actually ranks among the most significant hurdles in healthcare AI. Hospitals and insurers frequently rely on disparate software that struggles to interoperate, causing vital data to be scattered across EHRs, payer portals, billing systems, and other tools.
Tross aims to streamline how AI agents and health‑care apps interact with those systems. Its API layer provides a unified gateway to fragmented health‑care data and processes, enabling developers to craft solutions without needing a custom integration for each hospital or insurer.
Such capabilities could empower health‑care firms to automate processes like eligibility verification, patient‑record retrieval, claims handling, and administrative coordination. Yet interfacing with health‑care infrastructure is far more complex than linking to standard business applications; careful attention must be given to data privacy, security, regulatory compliance, accuracy, and access controls.
Consequently, Tross’s engineering and integration efforts are pivotal to its advancement. The firm must deliver a platform that is both robust for health‑care organisations and user‑friendly for developers, as even minor mistakes in a health‑care workflow can lead to delays, financial setbacks, or patient safety concerns.
All in Capital’s contribution was made via its Golden Ticket program, which supports early‑stage founders with funding and connects them to the U.S. startup ecosystem. The firm pointed to Tross’s initial customer traction and the founders’ hands‑on research—consulting U.S. health‑care teams—to grasp the challenge.
For Tross, the new capital enables the transition from early validation to a fuller product offering. The startup must deepen its integrations, attract additional customers, and demonstrate that its infrastructure can handle genuine health‑care workflows at scale.
Should it succeed, Tross may emerge as a key technology ally for the upcoming wave of health‑care AI firms. Its goal is not to supplant hospitals or clinicians, but to enhance the accessibility, connectivity, and automation‑readiness of the existing systems they rely on.
